{"transactions":[{"id":4617514,"issuer":{"id":4101,"kind":"organization","name":"Telix Pharmaceuticals Ltd","symbol":"TLX"},"owners":[{"id":54726,"kind":"person","name":"Smith Darren Charlton","position":1,"cik":"0002122447","reported_name":"Smith Darren Charlton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Group Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-14T23:20:14.000Z","date":"2026-09-07","kind":"purchase","planned":false,"acquired":true,"shares":2071,"price":9.656,"value":19997.576,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares purchased by the Reporting Person under the Employee Share Purchase Plan section of the Issuer's Equity Incentive Plan (\"AU ESPP\"), which shares were allocated on September 7, 2026, based on the Reporting Person's contributions  to the AU ESPP from January 1, 2026 - June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase price is recorded in Australian Dollars."}],"balance_after":13992,"source":{"system":"sec-edgar","filing":"0001628280-26-061944","document":"wk-form4_1789428011.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2122447/000162828026061944/wk-form4_1789428011.xml","form_type":"4"}},{"id":790141,"issuer":{"id":4101,"kind":"organization","name":"Telix Pharmaceuticals Ltd","symbol":"TLX"},"owners":[{"id":49413,"kind":"person","name":"Behrenbruch Christian","position":1,"cik":"0002037713","reported_name":"Behrenbruch Christian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"MD & Group CEO"}}],"security":"Ordinary Shares","published_at":"2026-05-07T01:32:08.000Z","date":"2026-04-29","kind":"purchase","planned":false,"acquired":true,"shares":33435,"price":14.87,"value":497178.45,"ownership":{"direct":false,"nature":"Elk River Holdings Pty Ltd"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase prices are reported in Australian Dollars."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is an average price. The shares were purchased in multiple transactions at prices ranging from $14.54 - $14.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Dr. Behrenbruch is the sole director and shareholder of Elk River Holdings Pty Ltd."}],"balance_after":20742935,"source":{"system":"sec-edgar","filing":"0001628280-26-031608","document":"wk-form4_1778117523.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2037713/000162828026031608/wk-form4_1778117523.xml","form_type":"4"}},{"id":790140,"issuer":{"id":4101,"kind":"organization","name":"Telix Pharmaceuticals Ltd","symbol":"TLX"},"owners":[{"id":49413,"kind":"person","name":"Behrenbruch Christian","position":1,"cik":"0002037713","reported_name":"Behrenbruch Christian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"MD & Group CEO"}}],"security":"Ordinary Shares","published_at":"2026-05-07T01:32:08.000Z","date":"2026-04-28","kind":"purchase","planned":false,"acquired":true,"shares":34500,"price":14.48,"value":499560.0,"ownership":{"direct":false,"nature":"Elk River Holdings Pty Ltd"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is an average price. The shares were purchased in multiple transactions at prices ranging from $14.42 - $14.58, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (SEC), upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase prices are reported in Australian Dollars."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Dr. Behrenbruch is the sole director and shareholder of Elk River Holdings Pty Ltd."}],"balance_after":20709500,"source":{"system":"sec-edgar","filing":"0001628280-26-031608","document":"wk-form4_1778117523.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2037713/000162828026031608/wk-form4_1778117523.xml","form_type":"4"}},{"id":823100,"issuer":{"id":4101,"kind":"organization","name":"Telix Pharmaceuticals Ltd","symbol":"TLX"},"owners":[{"id":54726,"kind":"person","name":"Smith Darren Charlton","position":1,"cik":"0002122447","reported_name":"Smith Darren Charlton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Group Chief Financial Officer"}}],"security":"Share Rights","published_at":"2026-04-01T23:14:36.000Z","date":"2026-03-29","kind":"exercise","planned":false,"acquired":false,"shares":1111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The share rights (SRs) were granted on January 1, 2025 and became vested and exercisable on March 5, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"expiration_date":"2028-03-31","underlying":"Ordinary Shares","underlying_shares":1111},"source":{"system":"sec-edgar","filing":"0001628280-26-022909","document":"wk-form4_1775085272.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026022909/wk-form4_1775085272.xml","form_type":"4"}},{"id":823099,"issuer":{"id":4101,"kind":"organization","name":"Telix Pharmaceuticals Ltd","symbol":"TLX"},"owners":[{"id":54726,"kind":"person","name":"Smith Darren Charlton","position":1,"cik":"0002122447","reported_name":"Smith Darren Charlton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Group Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-04-01T23:14:36.000Z","date":"2026-03-29","kind":"exercise","planned":false,"acquired":true,"shares":1111,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11921,"source":{"system":"sec-edgar","filing":"0001628280-26-022909","document":"wk-form4_1775085272.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026022909/wk-form4_1775085272.xml","form_type":"4"}}]}